Long-term amrinone therapy in patients with severe heart failure. Drug-dependent hemodynamic benefits despite progression of the disease

Carol S. Maskin, Robert Forman, Neal A. Klein, Edmund H. Sonnenblick, Thierry H. LeJemtel

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks). At initiation of therapy, the cardiac index increased from 1.74 ± 0.31 to 2.62 ± 0.52 (mean ± SD) liters/min/m2 (p < 0.01) and pulmonary capillary wedge pressure decreased from 26.5 ± 3.5 to 19.5 ± 5.4 mm Hg (p < 0.05). Symptoms were alleviated and exercise capacity increased from 5.9 ± 3.9 to 11.5 ± 4.5 minutes (p < 0.05). During long-term therapy, exercise capacity remained constants in three patients whereas it decreased in three others. All patients demonstrated an increase in heart size. Withdrawal of amrinone therapy precipitated severe symptoms at rest and hemodynamic deterioration in all patients. The cardiac index decreased from 1.87 ± 0.49 to 1.32 ± 0.30 liter/min/m2 (p < 0.05) and pulmonary capillary wedge pressure rose from 20.6 ± 2.9 to 28.8 ± 5.6 mm Hg (p < 0.05). These changes were reversed by reinstitution of therapy. Thus, amrinone-dependent hemodynamic benefits were demonstrated during long-term therapy without tachyphylaxis. In addition, progression of the underlying cardiac disease was observed in every patient.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalThe American Journal of Medicine
Volume72
Issue number1
DOIs
Publication statusPublished - Jan 1982
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this